Journal of Inflammation (Jun 2024)

Therapeutic potential of exosomes derived from mesenchymal stem cells for treatment of systemic lupus erythematosus

  • Shima Famil Samavati,
  • Reza Yarani,
  • Sara Kiani,
  • Zohreh HoseinKhani,
  • Masomeh Mehrabi,
  • Steven Levitte,
  • Rosita Primavera,
  • Shashank Chetty,
  • Avnesh S. Thakor,
  • Kamran Mansouri

DOI
https://doi.org/10.1186/s12950-024-00381-2
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Autoimmune diseases are caused by an imbalance in the immune system, producing autoantibodies that cause inflammation leading to tissue damage and organ dysfunction. Systemic Lupus Erythematosus (SLE) is one of the most common autoimmune diseases and a major contributor to patient morbidity and mortality. Although many drugs manage the disease, curative therapy remains elusive, and current treatment regimens have substantial side effects. Recently, the therapeutic potential of exosomes has been extensively studied, and novel evidence has been demonstrated. A direct relationship between exosome contents and their ability to regulate the immune system, inflammation, and angiogenesis. The unique properties of extracellular vesicles, such as biomolecule transportation, biodegradability, and stability, make exosomes a promising treatment candidate for autoimmune diseases, particularly SLE. This review summarizes the structural features of exosomes, the isolation/purification/quantification method, their origin, effect, immune regulation, a critical consideration for selecting an appropriate source, and their therapeutic mechanisms in SLE.